Navigation Links
Duke to test bird flu vaccine dosing

A clinical trial to test different strengths of a vaccine designed to fight avian influenza will begin this month at Duke University Medical Center.

The Duke study is part of a multicenter trial that will test a modified form of an investigational bird flu vaccine to determine whether the vaccine still triggers a strong immune response at lower doses.

The seven-month trial is sponsored by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. Also participating in the study are the University of Maryland, the University of Rochester and Baylor College of Medicine.

"We hope that by adding a compound called an adjuvant to the vaccine, we can create a stronger immune response to smaller doses of the vaccine," said Emmanuel Walter, M.D., associate director of the Duke Clinical Research Institute's Primary Care Research Consortium and leader of the Duke study. "If the smaller dose stimulates immunity against the virus, then more people could be immunized with existing supplies if a pandemic occurs," he said.

The study will use an inactivated flu virus vaccine based on a strain taken from a Vietnamese patient in 2004. "There is no live flu virus in the vaccine, and there is no risk of volunteers contracting bird flu or spreading it to others," Walter said.

The vaccine is designed to protect against the H5N1 strain of bird flu that has infected poultry in Asia, Europe and Africa and killed 101 humans. Initial trials in healthy adults showed the vaccine was safe and produced an immune response but required high doses and at least two injections to initiate a strong response, Walter said.

Trial participants will receive varying strengths of the H5N1 vaccine, either with or without an aluminum hydroxide adjuvant. An adjuvant works by increasing the body's immune response to a vaccine, Walter said. Aluminum hydroxide is commonly used in pediatric and adult vaccines, including those for wh
'"/>

Source:Duke University Medical Center


Page: 1 2

Related biology news :

1. Research advances quest for HIV-1 vaccine
2. A much-needed shot in the arm for HIV vaccine development
3. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
4. Gene vaccine for Alzheimers disease shows promising results
5. Influenza vaccine uses insect cells to speed development
6. Norovirus, AIDS vaccine and Hepatitis Virus
7. HIV vaccine trial breaks ground for future research
8. Live vaccines more effective against horse herpes virus
9. NIAID begins clinical trial of West Nile virus vaccine
10. Designing vaccines by computer
11. Wake Forest scientists find new combination vaccine effective against plague
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Duke test bird flu vaccine dosing

Breaking Biology News(10 mins):Study finds new relationship between gene duplication and alternative splicing in plants 2Study finds new relationship between gene duplication and alternative splicing in plants 3Self-destructing bacteria improve renewable biofuel production 2Self-destructing bacteria improve renewable biofuel production 3Spices halt growth of breast stem cells, U-M study finds 2Breaking medical and scientific news in angioplasty to be presented in San Francisco at TCT 2009 49237 1BurrellesLuce Executive to Speak on Measuring Communications Impact At Joint Seminar of Port Industry Group and PRSA 26apos 3Bs Detroit Chapter 49235 1BurrellesLuce Executive to Speak on Measuring Communications Impact At Joint Seminar of Port Industry Group and PRSA 26apos 3Bs Detroit Chapter 49235 2BurrellesLuce Executive to Speak on Measuring Communications Impact At Joint Seminar of Port Industry Group and PRSA 26apos 3Bs Detroit Chapter 49235 3BBK Worldwide Foresees Expanding Global Demand for Patient Recruitment Technology 49232 1BBK Worldwide Foresees Expanding Global Demand for Patient Recruitment Technology 49232 2BBK Worldwide Foresees Expanding Global Demand for Patient Recruitment Technology 49232 3BBK Worldwide Foresees Expanding Global Demand for Patient Recruitment Technology 49232 4